An Intermediate Alemtuzumab Schedule Reduces the Incidence of Mixed Chimerism Following Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistiocytosis

Ítems similars

• Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen
  per: Marsh, Rebecca A., et al.
  Publicat: (2015)
• Salvage Therapy of Refractory Hemophagocytic Lymphohistiocytosis with Alemtuzumab
  per: Marsh, Rebecca A., et al.
  Publicat: (2012)
• The successful use of alemtuzumab for treatment of steroid-refractory acute graft-versus-host disease in pediatric patients
  per: Khandelwal, Pooja, et al.
  Publicat: (2013)
• Thinking Beyond HLH: Clinical Features of Patients with Concurrent Presentation of Hemophagocytic Lymphohistiocytosis and Thrombotic Microangiopathy
  per: Gloude, Nicholas J., et al.
  Publicat: (2020)
• The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosis
  per: Hartz, Bernd, et al.
  Publicat: (2016)